당뇨병 환자에서 이상지질혈증의 치료
Dyslipidemia Treatment in Diabetes Mellitus Patients
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Cardiovascular disease (CVD) is the major cause of mortality and morbidity in patients with type 2 diabetes mellitus. The increasedrisk of CVD in subjects with type 2 diabetes mellitus involves multiple factors, including hypertension, smoking, albuminuria,and hypercholesterolemia. Of these, hypercholesterolemia is amenable to intervention. A large body of research rangingfrom molecular to population studies indicates that elevated low-density-lipoprotein cholesterol (LDL-C) is a major predictor ofCVD, including in the population with diabetes. Despite available therapies and increased attention to hypercholesterolemia, manypatients fail to achieve the LDL-C goals. A patient-tailored approach to dyslipidemia therapy, as determined by baseline LDL-Clevels, is an effective strategy for achieving target LDL-C levels.
Abstract
Cardiovascular disease (CVD) is the major cause of mortality and morbidity in patients with type 2 diabetes mellitus. The increasedrisk of CVD in subjects with type 2 diabetes mellitus involves multiple factors, including hypertension, smoking, albuminuria,and hypercholesterolemia. Of these, hypercholesterolemia is amenable to intervention. A large body of research rangingfrom molecular to population studies indicates that elevated low-density-lipoprotein cholesterol (LDL-C) is a major predictor ofCVD, including in the population with diabetes. Despite available therapies and increased attention to hypercholesterolemia, manypatients fail to achieve the LDL-C goals. A patient-tailored approach to dyslipidemia therapy, as determined by baseline LDL-Clevels, is an effective strategy for achieving target LDL-C levels.
참고문헌 (8)
- Bloomgarden ZT, "Diabetes and cardiovascular disease", Diabetes Care, 34, pp.e24~30 (2011)
- Webb DR, "Intensive multifactorial intervention improves modelled coronary heart disease risk in screen-detected Type 2 diabetes mellitus: a cluster randomized controlled trial", Diabet Med, 29, pp.531~540 (2012)
- Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, "Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in Adults (Adult Treatment Panel III)", JAMA, 285, pp.2486~2497 (2001)
- Grundy SM, "Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines", Circulation, 110, pp.227~239 (2004)
- Brunzell JD, "Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American diabetes association and the American college of cardiology foundation", Diabetes Care, 31, pp.811~822 (2008)
- European Association for Cardiovascular Prevention & Rehabilitation, "ESC Committee for Practice Guidelines (CPG) 2008-2010 and 2010- 2012 Committees. ESC", EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European society of cardiology (ESC) and the European atherosclerosis society (EAS), 2011, pp.32, 1769~1818
- Stone NJ, "2013 ACC", AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American college of cardiology, J Am Coll Cardiol, pp.2014, 63(25)[DOI]
- "Press statement" (2013)[URL]